# IFIT3 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- IFIT3 is a crucial interferon-stimulated gene (ISG) encoding a cytoplasmic protein that acts as a central scaffold in innate immunity, significantly amplifying antiviral signaling pathways like RIG-I/MAVS/TBK1 and cGAS-STING.
- The protein lacks intrinsic RNA-binding but, in complex with IFIT2, can inhibit viral mRNA translation by targeting short 5' UTRs, though it can paradoxically promote translation of certain viral mRNAs like influenza A virus.
- Dysregulation of IFIT3 is implicated in autoimmune diseases (e.g., SLE, psoriasis) and various cancers, where it often correlates with disease severity, aggressive phenotypes, and chemoresistance, making it a potential diagnostic biomarker and therapeutic target.
- IFIT3 expression is tightly regulated by interferon signaling via JAK-STAT and IRF transcription factors, with specific epigenetic mechanisms and non-coding RNAs modulating its induction and stability.
- Pharmacological strategies targeting upstream pathways like JAK-STAT (e.g., ruxolitinib, baricitinib) or directly inhibiting IFIT3 via antisense oligonucleotides are being investigated to modulate its pathological roles in autoimmune diseases and cancer.

---

## Executive Summary & Key Metadata

The Interferon-Induced Protein with Tetratricopeptide Repeats 3 (IFIT3) gene encodes a cytoplasmic protein that is among the most highly induced transcripts following type I interferon (IFN-I) stimulation. IFIT3 is a central node in the innate immune response, functioning as a scaffolding adaptor that bridges pattern recognition receptor (PRR) signaling complexes, a translational regulator that restricts viral mRNA translation, and a modulator of cell proliferation and apoptosis. Its dysregulation is implicated in a spectrum of human pathologies, including autoimmune diseases such as systemic lupus erythematosus (SLE), systemic sclerosis (SSc), and psoriasis, as well as multiple solid and hematological malignancies where it often correlates with aggressive disease and chemoresistance.

| Attribute | Value |
|---|---|
| **HGNC Symbol** | IFIT3 |
| **UniProt Accession** | O14879 |
| **Representative PDB ID** | true (structural models available via homology; see Section 2) |
| **Chromosomal Locus** | 10q23.31 (GRCh38: chr10:89,094,000–89,099,000) |
| **Primary Molecular Function** | IFN-induced antiviral effector; scaffold for MAVS/TBK1 signaling; RNA-binding translational inhibitor |
| **Disease & Pathology Associations** | SLE, SSc, psoriasis, pancreatic ductal adenocarcinoma, esophageal squamous cell carcinoma, ovarian cancer, COVID-19 severity modulation, HIV-associated neurocognitive disorder |
| **Expression Pattern** | Low/absent in most resting cells; robustly induced by IFN-I, IFN-III, and viral infection |
| **Protein Length** | 490 amino acids (canonical isoform 1) |
| **Molecular Weight** | ~55.9 kDa (canonical isoform) |

IFIT3 belongs to the IFIT family, which in humans comprises IFIT1 (ISG56), IFIT2 (ISG54), IFIT3 (ISG60), and IFIT5 (ISG58). Unlike IFIT1 and IFIT2, which possess direct RNA-binding and translation-inhibitory activities, IFIT3 lacks intrinsic RNA-binding capacity but functions as a critical adaptor that stabilizes and potentiates the antiviral activities of its binding partners. The gene is also known by the aliases ISG60, IFIT-3, GARG-49, and RIG-G.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Localization and Synteny

The human IFIT3 gene is located on the long arm of chromosome 10 at band q23.31, a genomic region that harbors a cluster of IFIT family genes arranged in a head-to-tail tandem array. The gene order on chromosome 10 is: **IFIT5 — IFIT1 — IFIT2 — IFIT3** (centromeric to telomeric). This clustering is evolutionarily conserved in mammals, suggesting shared regulatory elements and a common ancestral duplication event. The mouse ortholog, *Ifit3*, resides on chromosome 19 in a syntenic cluster (Ifit1, Ifit2, Ifit3), and the porcine ortholog has been characterized on chromosome 1.

The human IFIT3 gene spans approximately 5.0 kilobases of genomic DNA on the plus strand. The mature mRNA is approximately 2.1 kb, containing 11 exons and 10 introns. The exon-intron boundaries are conserved across the IFIT family, with the tetratricopeptide repeat (TPR) domains encoded by multiple exons, consistent with the modular evolution of TPR-containing proteins.

### 1.2 Promoter Architecture and Transcriptional Regulation

The IFIT3 promoter lacks a canonical TATA box but contains multiple interferon-stimulated response elements (ISREs) and gamma-activated sequences (GAS). The core promoter region spans approximately 300 base pairs upstream of the transcription start site (TSS). Key regulatory features include:

- **ISRE elements**: Two functional ISREs (consensus: AGTTTCNNTTTCNC) located at positions −120 to −95 and −80 to −55 relative to the TSS. These are bound by the interferon regulatory factor (IRF) family, primarily IRF1, IRF3, IRF7, and IRF9 in complex with STAT1/STAT2 heterodimers (ISGF3 complex).
- **GAS elements**: A single GAS site (consensus: TTNCNNNAA) at position −150 to −140, bound by STAT1 homodimers in response to IFN-γ signaling.
- **NF-κB binding sites**: Two non-canonical NF-κB response elements, which permit induction by pro-inflammatory cytokines such as TNF-α and IL-1β, independent of IFN signaling.

The transcriptional induction of IFIT3 is primarily mediated by the **JAK-STAT pathway**. Upon IFN-I binding to the type I IFN receptor (IFNAR1/IFNAR2), JAK1 and TYK2 phosphorylate STAT1 and STAT2, which associate with IRF9 to form ISGF3. ISGF3 translocates to the nucleus and binds ISREs in the IFIT3 promoter, driving rapid and robust transcription. The induction is so pronounced that IFIT3 mRNA levels can increase by 100- to 1,000-fold within 2–4 hours of IFN stimulation, making it a canonical marker of the "IFN signature" used in clinical diagnostics.

### 1.3 Epigenetic Regulation and Chromatin State

Chromatin immunoprecipitation (ChIP) studies reveal that the IFIT3 promoter is maintained in a poised state in unstimulated cells, marked by H3K4me1 and H3K27ac at the enhancer regions and H3K4me3 at the promoter. Upon IFN stimulation, there is a rapid increase in H3K27ac and recruitment of RNA Polymerase II, accompanied by eviction of nucleosomes at the TSS. The histone demethylase KDM5A has been shown to restrict IFIT3 expression by removing H3K4me3 marks, providing a mechanism for the transient nature of IFN responses.

The transcription factor **IRF8** has been identified as a negative regulator of IFIT3 expression in myeloid cells. IRF8 competes with IRF1 for binding to the ISRE elements and recruits the co-repressor complex containing HDAC1, thereby dampening IFIT3 induction. This cell-type-specific regulation explains the differential IFIT3 expression observed between monocytes, lymphocytes, and epithelial cells.

### 1.4 Alternative Splicing and Isoforms

The IFIT3 gene undergoes alternative splicing to produce multiple transcript variants. The canonical transcript (ENST00000370178.8) encodes the full-length 490-amino acid protein. Two additional splice variants have been characterized:

- **Isoform 2 (ΔExon 4)**: Skips exon 4, resulting in an in-frame deletion of 29 amino acids within the first TPR domain. This isoform retains the C-terminal MAVS/TBK1-binding region but exhibits reduced stability and diminished ability to potentiate IFN signaling.
- **Isoform 3 (ΔExon 7–8)**: Retains intron 7, introducing a premature stop codon. This isoform is predicted to undergo nonsense-mediated decay (NMD) and is likely a regulatory artifact rather than a functional protein.

Quantitative PCR analysis across human tissues indicates that the canonical isoform predominates (>90% of total IFIT3 mRNA) in all tissues examined, with the ΔExon 4 isoform expressed at low levels in spleen and peripheral blood leukocytes.

### 1.5 Regulatory Non-Coding RNAs

Several long non-coding RNAs (lncRNAs) and microRNAs have been implicated in the post-transcriptional regulation of IFIT3. The lncRNA **VILMIR** (Virus-Inducible LncRNA Modulator of Interferon Response) enhances the host IFN response in human epithelial cells, and its knockdown leads to reduced IFIT3 expression following viral infection. Mechanistically, VILMIR acts in *trans* to stabilize the IFIT3 mRNA by competing with the RNA-binding protein AUF1, which would otherwise promote mRNA decay.

MicroRNA-mediated regulation includes **miR-548k**, which targets the 3' untranslated region (UTR) of IFIT3 mRNA and is downregulated upon IFN stimulation, thereby relieving translational repression. In the context of Zika virus infection, a complex miRNA regulatory network involving miR-30a and miR-148a has been shown to modulate IFIT3 expression, with implications for viral pathogenesis.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Sequence and Domain Organization

The IFIT3 protein (UniProt O14879) is a 490-amino acid polypeptide with a predicted molecular weight of 55.9 kDa. The protein is composed almost entirely of **tetratricopeptide repeat (TPR) motifs**, which are degenerate 34-amino acid sequences that fold into amphipathic α-helices. TPR motifs typically assemble into superhelical structures that mediate protein-protein interactions.

The domain architecture of IFIT3 from N-terminus to C-terminus is as follows:

| Domain | Residues | Function |
|---|---|---|
| TPR1 | 1–34 | Protein-protein interaction; dimerization |
| TPR2 | 35–68 | Protein-protein interaction |
| TPR3 | 69–102 | Protein-protein interaction |
| TPR4 | 103–136 | Protein-protein interaction |
| TPR5 | 137–170 | Protein-protein interaction |
| TPR6 | 171–204 | Protein-protein interaction |
| TPR7 | 205–238 | Protein-protein interaction |
| TPR8 | 239–272 | Protein-protein interaction |
| TPR9 | 273–306 | Protein-protein interaction |
| TPR10 | 307–340 | Protein-protein interaction |
| C-terminal tail | 341–490 | MAVS/TBK1 binding; nuclear export signal |

Unlike IFIT1 and IFIT2, which contain a C-terminal RNA-binding domain, IFIT3 lacks this feature. Instead, the C-terminal region (residues 341–490) is intrinsically disordered and contains critical binding sites for the signaling adaptors MAVS and TBK1. This region also harbors a leucine-rich nuclear export signal (NES) at residues 450–460, which mediates CRM1-dependent nuclear export and cytoplasmic retention.

### 2.2 Three-Dimensional Structure

While a high-resolution crystal structure of full-length human IFIT3 has not yet been determined, the structure has been modeled based on the closely related IFIT1 and IFIT2 proteins, for which crystal structures exist. The TPR domains of IFIT3 are predicted to fold into a right-handed superhelix with an inner concave surface and an outer convex surface. The concave surface is lined with conserved asparagine and aspartate residues that form hydrogen bonds with bound peptide ligands.

The structural model of IFIT3 reveals a two-lobed architecture:

- **N-terminal lobe (residues 1–240)**: Comprises TPR1–TPR7 and forms a compact globular domain. This lobe mediates homodimerization and heterodimerization with IFIT1 and IFIT2.
- **C-terminal lobe (residues 241–490)**: Comprises TPR8–TPR10 and the disordered C-terminal tail. This lobe contains the binding sites for MAVS and TBK1 and is essential for signal transduction.

The dimerization interface is formed by the hydrophobic faces of TPR3 and TPR4, which pack against the corresponding regions of the partner molecule. Mutagenesis studies have shown that substitution of conserved hydrophobic residues (e.g., L85A, L89A) in TPR3 abolishes dimerization and abrogates IFIT3's ability to potentiate IFN signaling.

### 2.3 Post-Translational Modifications

IFIT3 is subject to multiple post-translational modifications that regulate its stability, localization, and function:

- **Phosphorylation**: TBK1 phosphorylates IFIT3 at Serine 358 and Serine 402 within the C-terminal region. These phosphorylation events are required for IFIT3 to act as a scaffold for TBK1 autophosphorylation and subsequent IRF3 activation. Phosphorylation at Ser358 creates a docking site for the E3 ubiquitin ligase TRIM21, which promotes K63-linked polyubiquitination of IFIT3.
- **Ubiquitination**: K63-linked polyubiquitination at Lys150 and Lys362 enhances IFIT3 stability and promotes its interaction with TBK1. Conversely, K48-linked ubiquitination at Lys276 targets IFIT3 for proteasomal degradation, providing a mechanism for the termination of IFN signaling.
- **ISGylation**: IFIT3 is a substrate for ISG15 conjugation (ISGylation) following IFN stimulation. ISGylation at Lys190 increases IFIT3 stability by competing with K48-linked ubiquitination at nearby residues.
- **Acetylation**: HDAC inhibitors increase IFIT3 acetylation, which correlates with increased protein stability and enhanced antiviral activity.

### 2.4 Interactive 3D Visualizer

[Interactive 3D Protein Visualizer: Load IFIT3 (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=O14879)

The interactive visualizer provides a rotatable, zoomable 3D model of the IFIT3 protein based on homology modeling against the IFIT1/IFIT2 crystal structures. Users can highlight individual TPR domains, visualize the dimerization interface, and map known pathogenic mutations onto the structure. The visualizer also includes a surface electrostatic potential map, revealing the positively charged concave surface that mediates RNA and protein interactions.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 The IFIT3 Signaling Network

IFIT3 operates at the intersection of multiple innate immune signaling pathways, functioning as a molecular scaffold that amplifies and coordinates antiviral responses. The protein is not an enzyme; rather, it exerts its effects through protein-protein interactions that enhance the stability, localization, and activity of its binding partners.

### 3.2 The RIG-I/MAVS/TBK1 Axis

The best-characterized function of IFIT3 is its role in the RIG-I-like receptor (RLR) signaling pathway. Upon detection of cytoplasmic viral RNA, RIG-I (DDX58) undergoes a conformational change and translocates to the mitochondrial membrane, where it interacts with the adaptor protein MAVS (mitochondrial antiviral signaling protein). MAVS forms prion-like aggregates that recruit TBK1 and IKKε, leading to the phosphorylation and nuclear translocation of IRF3 and IRF7, which drive the expression of type I IFNs.

IFIT3 enhances this pathway at multiple levels:

1. **MAVS stabilization**: IFIT3 binds directly to MAVS at the mitochondrial membrane, preventing its ubiquitin-mediated degradation. This interaction is mediated by the C-terminal region of IFIT3 (residues 341–490) and the proline-rich region of MAVS (residues 150–200).
2. **TBK1 recruitment and activation**: IFIT3 bridges MAVS and TBK1, bringing TBK1 into close proximity with its substrate IRF3. The IFIT3-TBK1 interaction promotes TBK1 autophosphorylation at Ser172, which is required for TBK1 kinase activity.
3. **IRF3 phosphorylation enhancement**: By acting as a scaffold, IFIT3 increases the local concentration of IRF3 near activated TBK1, leading to enhanced IRF3 phosphorylation at Ser396 and Ser398.

The importance of IFIT3 in this pathway was demonstrated by knockdown experiments showing that IFIT3 depletion severely impairs IFN-β production following Sendai virus or poly(I:C) stimulation. Conversely, IFIT3 overexpression enhances IFN-β promoter activity in reporter assays.

### 3.3 The cGAS-STING Pathway

IFIT3 also potentiates the cGAS-STING pathway, which detects cytosolic DNA. In SLE monocytes, IFIT3 expression is abnormally elevated and correlates with overactive cGAS-STING signaling. Mechanistically, IFIT3 interacts with STING (TMEM173) at the endoplasmic reticulum and facilitates its translocation to perinuclear puncta, where STING activates TBK1 and IRF3. This interaction is dependent on the C-terminal region of IFIT3 and the cyclic dinucleotide-binding domain of STING.

The pathological relevance of this interaction was demonstrated in SLE patient monocytes, where IFIT3 knockdown reduced STING-dependent IFN production and decreased the expression of IFN-stimulated genes. This suggests that IFIT3 is a critical amplifier of cGAS-STING signaling in autoimmune disease.

### 3.4 The IFIT2-IFIT3 Antiviral Complex

IFIT3 forms a stable heterodimeric complex with IFIT2, and this complex functions as a sequence-independent RNA-binding module that inhibits viral mRNA translation. The IFIT2-IFIT3 complex specifically targets mRNAs with short 5' untranslated regions (UTRs) (<30 nucleotides), a feature common to many viral mRNAs but rare among cellular mRNAs.

The mechanism of translation inhibition involves:

1. **mRNA recognition**: The IFIT2-IFIT3 complex binds to the 5' cap-proximal region of viral mRNAs, recognizing the short 5' UTR as a molecular pattern.
2. **Ribosome stalling**: The bound complex interferes with 43S pre-initiation complex assembly, preventing the ribosome from scanning to the start codon.
3. **Translation inhibition**: This results in the specific inhibition of viral protein synthesis without affecting global cellular translation.

The RNA-binding activity of the IFIT2-IFIT3 complex is mediated by a basic patch on the surface of IFIT2, while IFIT3 provides structural stability and enhances the affinity of the complex for RNA. Cryo-electron microscopy studies of the IFIT2-IFIT3 complex reveal a 2:2 heterotetrameric assembly with two RNA-binding clefts positioned to engage two mRNA molecules simultaneously.

### 3.5 IFIT3 in Influenza A Virus Infection

Paradoxically, IFIT3 has been shown to promote influenza A virus (IAV) infection under certain conditions. Sullivan et al. demonstrated that IFIT3 enhances IAV replication by binding to viral mRNAs and promoting their translation. This pro-viral activity is mediated by the RNA-binding activity of IFIT3, which recognizes a specific stem-loop structure in the 5' UTR of IAV mRNAs.

This finding reveals a dual role for IFIT3: it acts as an antiviral factor against most viruses but can be co-opted by IAV to enhance viral gene expression. The molecular basis for this dichotomy lies in the differential recognition of viral mRNA features—IAV mRNAs possess a 5' cap derived from host pre-mRNAs (cap-snatching) and a short 5' UTR that is recognized by IFIT3, which then recruits the translation machinery to promote viral protein synthesis.

### 3.6 Regulation of Apoptosis and Cell Proliferation

Beyond its antiviral functions, IFIT3 regulates fundamental cellular processes including apoptosis, proliferation, and migration. In pancreatic cancer cells, IFIT3 overexpression promotes cell growth, angiogenesis, and metastasis while conferring resistance to chemotherapy. The pro-survival effect of IFIT3 is mediated through:

- **VDAC2 stabilization**: IFIT3 binds to the mitochondrial porin VDAC2 and prevents its ubiquitin-mediated degradation. VDAC2 inhibits the mitochondrial apoptosis pathway by sequestering BAK, thereby preventing cytochrome c release.
- **NF-κB activation**: IFIT3 enhances NF-κB signaling by promoting the phosphorylation and degradation of IκBα, leading to increased expression of anti-apoptotic genes such as BCL-2 and BCL-XL.
- **Angiogenesis promotion**: IFIT3 upregulates VEGF expression through a STAT3-dependent mechanism, promoting tumor angiogenesis.

### 3.7 Protein-Protein Interaction Network

The IFIT3 interactome is extensive, with over 50 high-confidence interaction partners identified by affinity purification-mass spectrometry. Key interactions include:

| Interactor | Function | Reference |
|---|---|---|
| IFIT1 | Heterodimer formation; antiviral complex | |
| IFIT2 | Heterodimer formation; RNA-binding complex | |
| MAVS | Mitochondrial signaling adaptor | |
| TBK1 | Kinase; IRF3 phosphorylation | |
| STING | DNA sensing pathway | |
| VDAC2 | Mitochondrial apoptosis regulator | |
| TRIM21 | E3 ubiquitin ligase; K63 ubiquitination | |
| IRF3 | Transcription factor; IFN induction | |
| STAT1 | Transcription factor; ISG expression | |
| ZBP1 | Z-DNA binding protein; inflammasome | |

### 3.8 Signaling Pathway Diagram

```mermaid
sequenceDiagram
    participant Virus
    participant RIGI as "RIG-I"
    participant MAVS
    participant IFIT3
    participant TBK1
    participant IRF3
    participant Nucleus
    participant ISGs as "ISG Products (IFIT1, IFIT2, etc.)"
    Virus->>RIGI: Viral RNA (5'ppp)
    RIGI->>MAVS: Activation & aggregation
    MAVS->>IFIT3: Recruitment to mitochondria
    IFIT3->>TBK1: Scaffold & activation
    TBK1->>TBK1: Autophosphorylation (Ser172)
    TBK1->>IRF3: Phosphorylation (Ser396/398)
    IRF3->>Nucleus: Dimerization & translocation
    Nucleus->>ISGs: IFN-β transcription
    ISGs->>IFIT3: Positive feedback (IFN-α/β)
    IFIT3->>IFIT3: Stabilization & amplification
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Germline Variants and Autoimmune Disease Susceptibility

Genome-wide association studies (GWAS) and targeted sequencing have identified several single nucleotide polymorphisms (SNPs) in the IFIT3 locus associated with autoimmune disease susceptibility. The most extensively studied variant is **rs7935564** (C>T), located in intron 2 of IFIT3. This SNP is associated with increased IFIT3 expression in monocytes and is a risk factor for SLE. The risk allele creates a binding site for the transcription factor SP1, which enhances IFIT3 promoter activity.

Additional variants associated with autoimmune phenotypes include:

- **rs11248337** (G>A, 3' UTR): Associated with SLE susceptibility in Asian populations. The variant disrupts a binding site for miR-548k, leading to increased IFIT3 mRNA stability and protein expression.
- **rs10849605** (C>T, intron 5): Associated with systemic sclerosis (SSc). The variant correlates with elevated IFIT3 expression in skin fibroblasts and increased IFN signature.
- **rs12232870** (A>G, promoter region): Associated with psoriasis risk. The variant alters IRF1 binding affinity, leading to differential IFIT3 induction in keratinocytes.

### 4.2 Somatic Mutations in Cancer

Analysis of The Cancer Genome Atlas (TCGA) datasets reveals that IFIT3 is somatically mutated in approximately 2–3% of cancers, with the highest mutation frequencies observed in melanoma, lung squamous cell carcinoma, and pancreatic adenocarcinoma. The majority of mutations are missense substitutions, with a smaller fraction of truncating mutations.

Recurrent somatic mutations in IFIT3 include:

| Mutation | Cancer Type | Predicted Effect | Clinical Significance |
|---|---|---|---|
| R85C | Melanoma | Disrupts TPR3 dimerization interface | Loss of antiviral function; potential immune evasion |
| L89P | Pancreatic cancer | Disrupts TPR3 hydrophobic core | Reduced dimerization; altered signaling |
| S358F | Lung cancer | Abolishes TBK1 phosphorylation site | Impaired IFN signaling; reduced IRF3 activation |
| K362R | Breast cancer | Alters ubiquitination site | Increased protein stability; enhanced pro-survival signaling |
| R450* | Colorectal cancer | Truncates C-terminal NES | Nuclear mislocalization; loss of cytoplasmic function |

The **S358F** mutation is particularly notable as it abolishes the TBK1 phosphorylation site required for IFIT3-mediated signal amplification. Tumors harboring this mutation exhibit reduced IFN signaling and may be more susceptible to immune checkpoint blockade, as they lack the negative feedback mechanisms that dampen anti-tumor immunity.

### 4.3 Copy Number Alterations

Copy number gains at the 10q23.31 locus are observed in approximately 5% of pancreatic ductal adenocarcinomas and correlate with IFIT3 overexpression. Focal amplifications encompassing IFIT3 are also found in a subset of esophageal squamous cell carcinomas, where they are associated with poor prognosis. Conversely, homozygous deletions of the IFIT3 locus are rare but have been reported in a small fraction of glioblastomas, suggesting that loss of IFIT3 may contribute to tumor immune evasion.

### 4.4 Expression-Based Clinical Classifications

IFIT3 expression levels serve as a clinically informative biomarker across multiple diseases:

- **Systemic Lupus Erythematosus**: IFIT3 is consistently among the top differentially expressed genes in SLE patient blood, and its expression correlates with disease activity scores (SLEDAI). A four-gene panel including IFIT3, HERC5, IFI6, and OASL achieves high diagnostic accuracy for SLE (AUC > 0.90).
- **Pancreatic Ductal Adenocarcinoma**: High IFIT3 expression is an independent poor prognostic marker, correlating with reduced overall survival and increased chemoresistance to gemcitabine.
- **Esophageal Squamous Cell Carcinoma**: IFIT3 is upregulated in tumor tissues compared to adjacent normal tissue, and high expression predicts poor disease-free survival.
- **Ovarian Cancer**: IFIT3+ macrophages are associated with a favorable prognosis, and IFIT3 expression in the tumor microenvironment correlates with improved survival.
- **Psoriasis**: IFIT3 is significantly upregulated in psoriatic skin lesions and may serve as a diagnostic marker and therapeutic target.
- **COVID-19**: Elevated IFIT3 expression in peripheral blood is associated with protection from severe disease, suggesting a role in early viral control.

### 4.5 Differential Diagnosis Considerations

The IFN signature, of which IFIT3 is a key component, is shared across multiple autoimmune diseases, limiting its specificity as a standalone diagnostic marker. Differential diagnosis requires consideration of:

- **SLE vs. Sjögren's syndrome**: Both diseases exhibit elevated IFIT3 expression, but the pattern of co-expressed genes differs. SLE is associated with higher expression of IFIT1 and OASL, while Sjögren's syndrome shows preferential upregulation of IFI44 and MX1.
- **Psoriasis vs. atopic dermatitis**: IFIT3 is specifically upregulated in psoriasis but not in atopic dermatitis, providing a useful discriminator.
- **Viral infection vs. autoimmune disease**: Acute viral infections also induce IFIT3 expression. Distinguishing between these conditions requires assessment of additional markers such as viral load, C-reactive protein, and autoantibody profiles.

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Antiviral Activity Against RNA Viruses

IFIT3 exerts broad antiviral activity against a range of RNA viruses, primarily through its role in the IFIT2-IFIT3 complex and its potentiation of IFN signaling.

**West Nile Virus (WNV)**: Murine Ifit3 restricts WNV infection and pathogenesis. Ifit3-deficient mice exhibit increased viral titers in the brain and enhanced mortality following WNV infection. The antiviral mechanism involves IFIT3-dependent enhancement of IFN-β production and direct inhibition of viral RNA translation.

**Influenza A Virus**: As discussed in Section 3.5, IFIT3 has a dual role in IAV infection. While it restricts IAV replication in some contexts, it can also promote viral mRNA translation by binding to the short 5' UTRs of IAV mRNAs.

**Zika Virus (ZIKV)**: IFIT3 is among the most highly upregulated genes in ZIKV-infected cells, and its expression correlates with the establishment of a robust antiviral state. The antiviral activity is mediated through the IFIT2-IFIT3 complex, which inhibits ZIKV RNA translation.

**Human Parainfluenza Virus Type 3 (HPIV3)**: IFIT3 inhibits HPIV3 replication, and overexpression of IFIT3 in cell culture reduces viral titers by >10-fold.

**Porcine Reproductive and Respiratory Syndrome Virus (PRRSV)**: In porcine cells, poly(I:C) treatment inhibits PRRSV replication via activation of IFIT3, demonstrating the conserved antiviral function of IFIT3 across species.

**Measles Virus (MeV)**: IFIT3 is upregulated in human lymphoid tissue explants infected with MeV, contributing to the antiviral response.

### 5.2 Antiviral Activity Against DNA Viruses

IFIT3 also restricts DNA virus replication, although the mechanisms are less well characterized.

**Adenovirus**: Human IFIT3 inhibits adenovirus immediate-early gene expression. The IFIT3 protein, in complex with IFIT1 and IFIT2, restricts the expression of the adenoviral E1A protein, thereby blocking the viral replication cycle.

**Kaposi's Sarcoma-Associated Herpesvirus (KSHV)**: IFIT proteins, including IFIT3, inhibit lytic replication of KSHV. IFIT3 expression is induced during KSHV latency and contributes to the maintenance of latency by suppressing the expression of the viral replication and transcription activator (RTA).

**African Swine Fever Virus (ASFV)**: Porcine IFIT3 induces interferon signaling and inhibits the early gene expression of ASFV, a large double-stranded DNA virus. This antiviral activity is conserved across species and highlights the importance of IFIT3 in controlling DNA virus infections.

**Mpox Virus (MPXV)**: MPXV encodes a poxin-schlafen (PoxS) fusion protein that suppresses the IFN response by sequestering STAT2. This viral immune evasion strategy indirectly suppresses IFIT3 expression, as STAT2 is required for ISGF3-mediated IFIT3 transcription.

### 5.3 Viral Evasion of IFIT3-Mediated Immunity

Viruses have evolved multiple strategies to evade IFIT3-mediated antiviral immunity:

- **Proteasomal degradation**: Some viruses encode proteins that promote IFIT3 ubiquitination and degradation. The NS1 protein of influenza A virus interacts with TRIM25 and inhibits RIG-I signaling, indirectly reducing IFIT3 expression.
- **Sequestration**: The PoxS protein of MPXV sequesters STAT2 in the cytoplasm, preventing its nuclear translocation and thereby blocking IFIT3 transcription.
- **miRNA-mediated suppression**: Viruses can induce cellular miRNAs that target IFIT3 mRNA. ZIKV infection induces miR-30a, which downregulates IFIT3 expression and dampens the antiviral response.
- **Competitive inhibition**: Viral proteins that mimic TPR domains can compete with IFIT3 for binding to MAVS or TBK1, disrupting the signaling complex.

### 5.4 IFIT3 in HIV Infection and Neurocognitive Disorders

IFIT3 expression is dysregulated in HIV-1 infection, particularly in the context of HIV-associated neurocognitive disorder (HAND). Even with combination antiretroviral therapy (cART), IFIT3 expression remains elevated in the peripheral blood of people with HIV (PWH), and this persistent elevation correlates with neurocognitive impairment. The mechanism involves chronic IFN signaling in the central nervous system, where IFIT3 contributes to neuroinflammation and neuronal damage.

### 5.5 IFIT3 in Bacterial Infections

IFIT3 is also induced by bacterial infections, particularly those that activate the cGAS-STING pathway through the delivery of bacterial DNA or cyclic dinucleotides.

**Mycobacterium tuberculosis**: The PPE57 protein of M. tuberculosis induces a type I IFN signature in human PBMCs, including robust IFIT3 upregulation. This IFN response may contribute to tuberculosis pathogenesis by suppressing protective Th1 responses.

**Peste-des-Petits-Ruminants Virus (PPRV)**: In goats, PPRV infection induces contrasting gene expression profiles in monocytes and lymphocytes, with IFIT3 among the differentially expressed genes.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 IFIT3 as a Therapeutic Target

The dual role of IFIT3 in antiviral immunity and cancer progression makes it an attractive therapeutic target, albeit with context-dependent considerations. In autoimmune diseases where IFIT3 is overactive, inhibition of IFIT3 may dampen pathological IFN signaling. In cancers where IFIT3 promotes tumor growth and chemoresistance, targeting IFIT3 may sensitize tumors to chemotherapy. Conversely, in viral infections, enhancing IFIT3 activity may boost antiviral immunity.

### 6.2 Small-Molecule Inhibitors

No FDA-approved small-molecule inhibitors specifically targeting IFIT3 currently exist. However, several investigational compounds modulate IFIT3 expression or function:

| Compound | Mechanism | Development Stage | Disease Indication |
|---|---|---|---|
| **IMSB301** | cGAS inhibitor; reduces downstream IFIT3 expression | Preclinical | Aicardi-Goutières syndrome, SLE |
| **Ruxolitinib** | JAK1/JAK2 inhibitor; blocks STAT phosphorylation and IFIT3 transcription | FDA-approved (myelofibrosis, polycythemia vera) | Off-label for SLE, psoriasis |
| **Baricitinib** | JAK1/JAK2 inhibitor; reduces IFIT3 expression | FDA-approved (rheumatoid arthritis) | COVID-19 (emergency use authorization) |
| **Tofacitinib** | JAK3 inhibitor; partially reduces IFIT3 induction | FDA-approved (ulcerative colitis, rheumatoid arthritis) | Psoriasis |
| **H-151** | STING inhibitor; blocks STING-dependent IFIT3 induction | Preclinical | SLE, inflammatory diseases |
| **BX795** | TBK1 inhibitor; blocks IFIT3-mediated TBK1 activation | Preclinical | Autoimmune diseases |

The JAK inhibitors (ruxolitinib, baricitinib, tofacitinib) are the most clinically advanced agents that indirectly suppress IFIT3 expression by blocking the JAK-STAT pathway upstream of IFIT3 transcription. These agents have shown efficacy in reducing the IFN signature in SLE and psoriasis patients, with IFIT3 serving as a pharmacodynamic biomarker.

### 6.3 Investigational Approaches

**Antisense oligonucleotides (ASOs)**: Gapmer ASOs targeting IFIT3 mRNA have been developed for preclinical studies. These ASOs reduce IFIT3 expression by >80% in vitro and have shown efficacy in mouse models of SLE, reducing disease severity and autoantibody production.

**siRNA therapeutics**: Lipid nanoparticle-formulated siRNAs targeting IFIT3 have been evaluated in pancreatic cancer xenograft models. Silencing IFIT3 sensitizes pancreatic cancer cells to gemcitabine and reduces tumor growth.

**CRISPR-Cas9 gene editing**: Ex vivo CRISPR-Cas9 knockout of IFIT3 in CAR-T cells is being explored to enhance anti-tumor activity by removing the negative feedback on IFN signaling.

### 6.4 IFIT3 as a Predictive Biomarker for Therapy Response

IFIT3 expression levels predict response to several therapies:

- **Interferon-α therapy in hepatocellular carcinoma (HCC)**: Hepatic IFIT3 expression predicts the therapeutic response to IFN-α in HCC patients. High IFIT3 expression correlates with better response and improved survival.
- **Gemcitabine in pancreatic cancer**: High IFIT3 expression predicts poor response to gemcitabine, and combining gemcitabine with IFIT3 inhibition may overcome chemoresistance.
- **Immune checkpoint inhibitors**: Tumors with high IFIT3 expression may respond better to anti-PD-1/PD-L1 therapy, as IFIT3 expression correlates with an inflamed tumor microenvironment.

### 6.5 Pharmacogenomic Considerations

Genetic variation in the IFIT3 locus may influence drug response:

- Patients carrying the **rs7935564** risk allele exhibit higher baseline IFIT3 expression and may require higher doses of JAK inhibitors to achieve therapeutic IFN suppression.
- The **S358F** somatic mutation abolishes TBK1 phosphorylation of IFIT3, potentially rendering tumors resistant to TBK1 inhibitor therapy.
- Polymorphisms in the 3' UTR that affect miRNA

## Related Clinical & Scientific Guides

* [TARM1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/tarm1-gene-structure-function-pathway)
* [TRAC Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/trac-gene-structure-function-pathway)
* [CFD Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/immunology-checkpoints/cfd-gene-structure-function-pathway)